$APDN
APPLIED DNA SCIENCES INC

2024 Q1 Form 10-Q Financial Statement

#000141057824000021 Filed on February 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $929.6K $891.2K
YoY Change -78.91% -83.07%
Cost Of Revenue $634.0K $660.1K
YoY Change -75.62% -77.12%
Gross Profit $295.7K $231.1K
YoY Change -83.64% -90.28%
Gross Profit Margin 31.8% 25.93%
Selling, General & Admin $3.000M $3.084M
YoY Change -14.83% 17.48%
% of Gross Profit 1014.78% 1334.66%
Research & Development $913.2K $935.8K
YoY Change -7.64% -3.65%
% of Gross Profit 308.88% 404.94%
Depreciation & Amortization $186.3K $299.0K
YoY Change -45.91% -11.79%
% of Gross Profit 63.02% 129.36%
Operating Expenses $3.913M $4.020M
YoY Change -13.26% 11.77%
Operating Profit -$3.618M -$3.789M
YoY Change 33.79% 210.84%
Interest Expense $15.35K $33.32K
YoY Change 321.7% 802.98%
% of Operating Profit
Other Income/Expense, Net $4.581K -$13.54K
YoY Change 593.04% -253.04%
Pretax Income -$4.494M -$1.130M
YoY Change -915.31% -70.6%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.470M -$1.105M
YoY Change -859.84% -71.25%
Net Earnings / Revenue -480.89% -124.01%
Basic Earnings Per Share -$5.31 -$0.09
Diluted Earnings Per Share -$5.31 -$0.09
COMMON SHARES
Basic Shares Outstanding 16.98M 13.69M
Diluted Shares Outstanding 871.3K 13.67M

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.150M $3.359M
YoY Change -74.37% -73.91%
Cash & Equivalents $3.150M $3.359M
Short-Term Investments
Other Short-Term Assets $470.3K $403.0K
YoY Change -38.0% -56.42%
Inventory $335.9K $377.3K
Prepaid Expenses
Receivables $408.9K $450.8K
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.365M $4.590M
YoY Change -71.62% -74.96%
LONG-TERM ASSETS
Property, Plant & Equipment $367.8K $539.3K
YoY Change -76.65% -71.09%
Goodwill
YoY Change
Intangibles $2.699M $2.699M
YoY Change
Long-Term Investments
YoY Change
Other Assets $750.0K $967.6K
YoY Change 0.0% 877.42%
Total Long-Term Assets $4.811M $5.323M
YoY Change 26.74% 170.93%
TOTAL ASSETS
Total Short-Term Assets $4.365M $4.590M
Total Long-Term Assets $4.811M $5.323M
Total Assets $9.176M $9.913M
YoY Change -52.15% -51.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.128M $1.017M
YoY Change -31.53% -49.73%
Accrued Expenses $1.444M $1.517M
YoY Change -16.29% 46.86%
Deferred Revenue $51.29K $54.04K
YoY Change -81.9% -80.27%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.623M $2.588M
YoY Change -28.24% -22.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.044M $2.513M
YoY Change 8.86% -67.82%
Total Long-Term Liabilities $6.044M $2.513M
YoY Change 8.86% -67.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.623M $2.588M
Total Long-Term Liabilities $6.044M $2.513M
Total Liabilities $9.351M $5.785M
YoY Change 1.56% -48.07%
SHAREHOLDERS EQUITY
Retained Earnings -$308.3M -$303.6M
YoY Change 4.23% 2.46%
Common Stock $308.2M $307.9M
YoY Change 0.8% 0.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$48.15K $4.232M
YoY Change
Total Liabilities & Shareholders Equity $9.176M $9.913M
YoY Change -52.15% -51.16%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$4.470M -$1.105M
YoY Change -859.84% -71.25%
Depreciation, Depletion And Amortization $186.3K $299.0K
YoY Change -45.91% -11.79%
Cash From Operating Activities -$3.210M -$3.758M
YoY Change -1597.27% 57.68%
INVESTING ACTIVITIES
Capital Expenditures $14.83K
YoY Change -72.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.83K
YoY Change -72.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.015M -35.08K
YoY Change
NET CHANGE
Cash From Operating Activities -3.210M -3.758M
Cash From Investing Activities -14.83K
Cash From Financing Activities 3.015M -35.08K
Net Change In Cash -209.4K -3.793M
YoY Change -230.83% 62.21%
FREE CASH FLOW
Cash From Operating Activities -$3.210M -$3.758M
Capital Expenditures $14.83K
Free Cash Flow -$3.225M
YoY Change -2114.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0000744452
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q4 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q4 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
001-36745
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
Applied DNA Sciences, Inc.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
CY2023Q4 dei City Area Code
CityAreaCode
631
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
240-8800
CY2023Q4 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q4 dei Trading Symbol
TradingSymbol
APDN
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16978703
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3359045
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
450757
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255502
CY2023Q4 us-gaap Inventory Net
InventoryNet
377291
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
402953
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389241
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4590046
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8126570
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
539319
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1117317
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1237762
CY2023Q4 apdn Capitalized Transaction Costs For Asset Purchase Transaction
CapitalizedTransactionCostsForAssetPurchaseTransaction
217553
CY2023Q4 us-gaap Assets
Assets
9913210
CY2023Q3 us-gaap Assets
Assets
13651577
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2023876
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
510028
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498598
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
54035
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76435
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2587939
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2845421
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
227999
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
607288
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
739162
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2023Q4 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
1646000
CY2023Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4285000
CY2023Q4 us-gaap Liabilities
Liabilities
5784808
CY2023Q3 us-gaap Liabilities
Liabilities
8779165
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13721820
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13721820
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13658520
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13658520
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13722
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
13659
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307848612
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307384647
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303630004
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302447147
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4232330
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4951159
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-103928
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-78747
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4128402
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9913210
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13651577
CY2023Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
891164
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5262752
CY2023Q4 us-gaap Cost Of Revenue
CostOfRevenue
660067
CY2022Q4 us-gaap Cost Of Revenue
CostOfRevenue
2885069
CY2023Q4 us-gaap Gross Profit
GrossProfit
231097
CY2022Q4 us-gaap Gross Profit
GrossProfit
2377683
CY2023Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3084348
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2625357
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
935815
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
971304
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
4020163
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
3596661
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3789066
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1218978
CY2023Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
33323
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3686
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2639000
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2637800
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13538
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8846
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1130281
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3844246
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1130281
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-25181
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-874
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-1105100
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3843372
CY2023Q4 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
77757
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1182857
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3843372
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13673433
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13673433
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12908520
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12908520
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93748
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340705
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-45566
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1130281
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4128402
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1130281
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2023Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
298951
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
338918
CY2022Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2639000
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2637800
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
340705
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
93748
CY2022Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-290022
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
195254
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
695912
CY2023Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
47264
CY2022Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-125230
CY2023Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13712
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-133374
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-383423
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-586236
CY2023Q4 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
11599
CY2022Q4 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-289677
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3757679
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2383106
CY2022Q4 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45000
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
45566
CY2023Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
80642
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-35076
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3792755
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2338106
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4109045
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12877179
CY2023Q4 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2022Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2023Q4 apdn Capitalized Transaction Costs Included In Accounts Payable
CapitalizedTransactionCostsIncludedInAccountsPayable
136911
CY2023Q4 apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
77757
CY2022Q4 apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
20619
CY2023Q4 apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1130281
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3757679
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3359045
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the financial statements in conformity with Accounting Principles Generally Accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p>
CY2023Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
891164
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5262752
CY2023Q4 us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
11599
CY2023Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
40035
CY2023Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7684872
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8301729
CY2023Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of December 31, 2023, the Company had cash and cash equivalents of approximately $3.1 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the three-month period ended December 31, 2023 included an aggregate of 25% from one customer within the MDx Testing Services segment and an aggregate of 22% from one customer within the DNA Tagging and Security Products and Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the three-month period ended December 31, 2022 included an aggregate of 83% from two customers within the MDx Testing Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Two customers accounted for 56% of the Company’s accounts receivable at December 31, 2023 and three customers accounted for 60% of the Company’s accounts receivable at September 30, 2023.</p>
CY2023Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
3100000
CY2023Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q4 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5220588
CY2023Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.68
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
172404
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
212079
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
36866
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
19859
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
168021
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
98089
CY2023Q4 us-gaap Inventory Net
InventoryNet
377291
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1017057
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072161
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
907777
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1138235
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99042
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59992
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2023876
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 apdn Maximum Aggregate Offering Price For Sale Of Stock
MaximumAggregateOfferingPriceForSaleOfStock
6397939
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
61200
CY2023Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
45480
CY2023Q4 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
77757
CY2023Q4 apdn Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3000
CY2023Q4 apdn Weighted Average Price Per Share Warrant Exercised
WeightedAveragePricePerShareWarrantExercised
5.60
CY2023Q4 apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
4375
CY2023Q4 apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
2.82
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5213213
CY2023Q4 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.32
CY2023Q4 apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2023Q4 apdn Lessee Operating Lease Terminable Term
LesseeOperatingLeaseTerminableTerm
P1M
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2023Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
174419
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
148826
CY2023Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
891164
CY2023Q4 us-gaap Gross Profit
GrossProfit
231097
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5262752
CY2022Q4 us-gaap Gross Profit
GrossProfit
2377683
CY2023Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
33323
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3686
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2639000
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2637800
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13538
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8846
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1130281
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3844246
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4285000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
2639000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1646000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000021-index-headers.html Edgar Link pending
0001410578-24-000021-index.html Edgar Link pending
0001410578-24-000021.txt Edgar Link pending
0001410578-24-000021-xbrl.zip Edgar Link pending
apdn-20231231.xsd Edgar Link pending
apdn-20231231x10q.htm Edgar Link pending
apdn-20231231xex10d3.htm Edgar Link pending
apdn-20231231xex10d3001.jpg Edgar Link pending
apdn-20231231xex10d3002.jpg Edgar Link pending
apdn-20231231xex31d1.htm Edgar Link pending
apdn-20231231xex31d2.htm Edgar Link pending
apdn-20231231xex32d1.htm Edgar Link pending
apdn-20231231xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
apdn-20231231_def.xml Edgar Link unprocessable
apdn-20231231_lab.xml Edgar Link unprocessable
apdn-20231231_pre.xml Edgar Link unprocessable
apdn-20231231x10q_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
apdn-20231231_cal.xml Edgar Link unprocessable